key: cord-1047677-7qraitsn authors: Tchelebi, Leila T.; Haustermans, Karin; Scorsetti, Marta; Hosni, Ali; Huguet, Florence; Hawkins, Maria A.; Dawson, Laura A.; Goodman, Karyn title: Recommendations on the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19 date: 2020-04-13 journal: Radiother Oncol DOI: 10.1016/j.radonc.2020.04.010 sha: 6bacdb5a14a36c805b63079c903b660d1fb55934 doc_id: 1047677 cord_uid: 7qraitsn Abstract As of April 6, 2020, there are over 1,200,000 reported cases and 70,000 deaths worldwide due to COVID-19, the disease caused by the SARS-CoV-2 virus, and these numbers rise exponentially by the day.[1] According to the Centers for Disease Control (CDC), the most effective means of minimizing the spread of the virus is through reducing interactions between individuals.[2] We performed a review of the literature, as well as national and international treatment guidelines, seeking data in support of the RADS principle (Remote visits, Avoid radiation, Defer radiation, Shorten radiation)[3] as it applies to gastrointestinal cancers. The purpose of the present work is to guide radiation oncologists managing patients with gastrointestinal cancers during the COVID-19 crisis in order to maintain the safety of our patients, while minimizing the impact of the pandemic on cancer outcomes. As of April 6, 2020, there are over 1,200,000 reported cases and 70,000 deaths worldwide due to COVID-19, the disease caused by the SARS-CoV-2 virus. 1 According to the CDC, the most effective means of minimizing the spread of the virus is through reducing interactions between individuals. Patients with cancer are at particularly high risk of becoming infected with COVID-19 4 and of developing severe complications or dying of the disease. 5 In fact, in one report detailing the incidence and outcomes of COVID-19 infection in a cohort of cancer patients treated at a tertiary cancer center in Wuhan, the rate of death was a staggering 25%. 6 As clinicians caring for cancer patients during this pandemic, we must carefully balance efforts to minimize patient visits to the hospital, while still adequately treating their malignancies. Not only are we required to change practice in order to minimize the number of patient visits to the clinic to decrease the risk of exposure to coronavirus, but practices may be forced to change due to operating room closures and staff shortages, as employees become ill and are forced to stay home and quarantine. As inpatient wards are becoming less safe for cancer patients due to the increased risk of exposure to the disease, treatment of patients in an outpatient setting is preferred when possible. During the COVID-19 pandemic, the RADS framework laid out by Zaorsky et al (Remote visits, Avoid radiation, Defer radiation, Shorten radiation) should be followed. 3 Radiation therapy should be deferred or not recommended, e.g. when the evidence for benefit is controversial or the overall benefit to the patient is estimated to be small. The National Institute for Health and Care Excellence issued a guideline which includes a risk stratification system for patients needing radiation to help in making management decisions. 7 When radiation therapy is indicated, efforts should be made to reduce the number of treatment fractions delivered. Reducing the number of patients receiving radiation therapy, as well as the number of treatments received, is critically important during the COVID-19 pandemic, not only to benefit the patient being treated, but also for a number of other reasons beyond the individual benefit. First, it minimizes exposure and risk of all patients and staff to the virus. Second, radiation therapy, especially when delivered concurrently with chemotherapy, may cause lymphopenia which is likely to persist over the course of therapy, resulting in immunosuppression and thus increased susceptibility to the virus. This can be minimized with shorter treatment courses, or sequential versus concurrent chemoradiation therapy (CRT). Finally, each time a COVID-19-positive patient is treated, treatment rooms and machines must be decontaminated, resulting in over-utilization of resources, currently in limited supply. While reduction in treatment may be necessary for patient safety, and due to resource limitations, it is important to follow safe practices and to respect organ at risk constraints. Therefore, recommendations provided below are based on data showing the safety and efficacy of alternative treatment approaches. It is important to keep in mind that practices are likely to have varying constraints in terms of supplies and personnel depending on location, thus the following recommendations may not apply to all clinics equally. Furthermore, we acknowledge that countries and institutional practices may differ in their approach to treatment, as evidenced by variable recommendations by contributing authors for certain subsites in this manuscript. Thus, there may be variation in practice among institutions. We performed a review of the literature, in addition to national and international treatment guidelines, seeking data in support of reducing radiation treatment delivery. It should be noted that while data-driven, not all recommendations are based on level 1 data and thus these recommendations are intended to guide clinicians managing patients with gastrointestinal cancers whose resources (specifically the operating rooms) have been heavily strained by the COVID-19 pandemic. The purpose of the present work is to help clinicians maintain the safety of our patients without compromising cancer outcomes, during a time when treatment practices are being forced to change week to week or even day to day. Table 1 c. T2N0: Surgery alone for adenocarcinoma and neoadjuvant CRT for SCC. 10 2. Locally advanced (T2N+ or T3+/Nany) operable esophageal carcinoma: a. Neoadjuvant CRT: Pre-operative CRT is a standard of care and should be given using the shortest fractionation scheme possible. Based on the CROSS trial, 41 .4Gy in 23 fractions with concurrent weekly carboplatin/paclitaxel is preferred. 11 In centers where staffing is particularly limited, and in which minimizing the number of fractions is of critical importance, the Walsh regimen of 40Gy in 15 fractions can be considered. 12 However, concurrent carboplatin/paclitaxel or FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) 13 is preferred. b. Induction chemotherapy: To delay the initiation of daily radiotherapy in centers were these facilities may be strained for staff and resources, induction chemotherapy can be considered prior to CRT. [14] [15] [16] [17] It should be noted that this was a controversial recommendation, not supported by all authors, based on data from the CALGB 80803 trial, which has only been published in abstract form. CALGB 80803 demonstrated feasibility and promising outcomes for patients undergoing PET-directed therapy for esophageal adenocarcinoma with treatment based on response after 6 weeks of induction FOLFOX or carboplatin and paclitaxel. 18 . c. Surgery: Patients should undergo re-staging scans and be referred for surgery [6] [7] [8] weeks after completion of CRT in centers where surgery can still be performed. In centers where surgical procedures have been discontinued for the forseeable future due to the COVID-19 crisis, management should follow that of inoperable esophageal cancer (see below). If there has been a complete clinical response to neoadjuvant treatment, consider close follow-up with surgery reserved for salvage. For patients with squamous cell histology, consider CRT alone, without surgery, based on the 49% pathological complete response rate in the CROSS trial. 11 3. Inoperable esophageal cancer: a. Definitive CRT: For inoperable patients, the maximum dose of radiation should not exceed 50Gy in 25 fractions, as higher doses are ineffective and may even be detrimental. 19; 20 Weekly carboplatin/paclitaxel is the preferred concurrent chemotherapy regimen due to only once weekly administration. Concurrent FOLFOX is another good option due to administration every 2 weeks. 13 For centers where radiation facilities are particularly strained, 40Gy in 15 fractions can be considered. This should be followed by 2 cycles of chemotherapy (with fluorouracil and cisplatin) as per RTOG 85-01. 21; 22 4. Definitive RT: Patients who are not suitable for chemotherapy can receive RT with a hypofractionated regimen of either 50Gy in either 16 or 20 fractions. 23 It should be noted that this recommendation was somewhat controversial among authors due to concerns over the potential for increased late toxicity. 35 Although radiation therapy has been suggested to have a benefit following systemic therapy, due to the lack of level 1 data, radiation therapy should not be used in the adjuvant setting during COVID-19. b. Positive margins: For positive surgical margins or node positive disease, a survival benefit to adjuvant radiation after chemotherapy has been suggested; 36 however, given the lack of level 1 data, adjuvant radiation therapy should be deferred during COVID-19. Concurrent CRT is not recommended. 37; 38 While 15-fractions has been favored over SBRT for intrahepatic cholangiocarcinoma where there is concern over biliary stricture, 39 during COVID-19, SBRT is an acceptable alternative. 3-5 fractions should be consdered for central lesions, and 1-3 fractions for peripheral lesions (please refer to Table 1 for recommended doses). 40 Appropriate biliary stenting should be used prior to all radiation therapy, when available. For centers with particularly strained radiation resources, radiotherapy may be reserved for isolated local progression. Similarly when cure is not possible (multifocal cholangiocarcinoma or node positive cancer), radiation therapy should be deferred until progression, and only if the cancer remains localized. a. Neoadjuvant chemotherapy: In order to delay surgery and the associated inpatient hospital stay or in centers where surgery has been suspended, neoadjuvant therapy can be considered. [41] [42] [43] b. Neoadjuvant radiation therapy: For cases that remain borderline resectable even after a complete course of six months of neoadjuvant chemotherapy, SBRT in 5 fractions (of 30-33Gy) can be considered. 44 For centers without SBRT capability, 25Gy in 5 fractions, or 30Gy in 10 fractions with concurrent gemcitabine, can be used. 45 While SBRT is not standard in the management of borderline pancreatic cancers, it may be considered as an alternative to continuing chemotherapy until the patient is able to safely undergo surgery in order to reduce the risk of ongoing chemotherapy and its related toxicity. Further, radiation in this context can allow for local disease control until the tumor can be a. Definitive CRT: Patients with anal cancer can be cured with the combination of chemotherapy and radiation and therefore deviations from the standard treatment approach (capecitabine or 5-FU plus mitomycin-C plus radiation therapy) are not indicated, even during this global pandemic. 27 Radiation therapy is recommended to be delivered utilizing a simultaneous integrated boost (SIB) approach in 28-30 fractions as per RTOG 0529. 60 Patients with T1N0 can be treated with lower dose of radiation such as 40-50Gy/20-25 fractions, or an even lower dose using an approach similar to the Nigro protocol (i.e. 30Gy/10 fractions) if limited by resources/staff. Patients who are not candidates to receive concurrent chemotherapy (due to comorbidities or poor performance status), can be treated with a hypofractionated regimen of 36-40Gy in 20 fractions to the elective volume with an SIB to 50Gy to the primary tumor. 61; 62 Oligo-metastases from colorectal cancer How to protect yourself from coronavirus disease Prostate Cancer Radiotherapy Recommendations in Response to COVID-19 Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standarddose radiation therapy A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus Hypofractionated Radiotherapy in Oesophageal Cancer for Patients Unfit for Systemic Therapy: A Retrospective Single-Centre Analysis A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC) Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses The role of palliative radiotherapy for haemostasis in unresectable gastric cancer: a single-institution experience Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet. Oncology Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma The challenge of inoperable hepatocellular carcinoma (HCC): results of a singleinstitutional experience on stereotactic body radiation therapy (SBRT) Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05) Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis. Cancer Celiac Plexus Radiosurgery, a New Modality for Cancer Pain Management – Final Results of a Phase II Clinical Trial International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study OC-0429: Neoadjuvant chemoradiotherapy or 5x5 Gy followed by chemotherapy in rectal cancer: the RAPIDO trial Adenocarcinoma of the rectum treated by radical external radiation therapy RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies Individualized image guided iso-NTCP based liver cancer SBRT Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis Highlights  Cancer patients are at high risk of dying from COVID-19  Treatment practices are being forced to change rapidly due to resource and staff shortages  Social distancing means minimizing patient-staff interactions  Data-driven recommendations are needed to guide clinicians managing cancer patients  Goal is to minimize impact of the pandemic on cancer outcomes chemo Abbreviations: CRT, chemoradiotherapy; RT, radiation therapy; FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; TACE, trans-arterial chemo-embolization; Y-90, yttrium-90; SBRT, stereotactic body radiation therapy; BR, borderline resectable; Gy, gray; Fx, fractions *Some authors suggest induction chemotherapy with either FOLFOX or carboplatin/paclitaxel in order to delay radiotherapy when radiation staffing may be limited Neoadjuvant radiation was not universally recommended in the case of BR pancreatic cancer Please note, the above fractionation schemes are only recommended if the organ at risk doseconstraints can be achieved.